291 related articles for article (PubMed ID: 21412389)
21. The future of antiretroviral therapy: challenges and needs.
Moreno S; López Aldeguer J; Arribas JR; Domingo P; Iribarren JA; Ribera E; Rivero A; Pulido F;
J Antimicrob Chemother; 2010 May; 65(5):827-35. PubMed ID: 20228080
[TBL] [Abstract][Full Text] [Related]
22. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.
Dubé MP; Sprecher D; Henry WK; Aberg JA; Torriani FJ; Hodis HN; Schouten J; Levin J; Myers G; Zackin R; Nevin T; Currier JS;
Clin Infect Dis; 2000 Nov; 31(5):1216-24. PubMed ID: 11073755
[TBL] [Abstract][Full Text] [Related]
23. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
Wilson LE; Gallant JE
Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
[TBL] [Abstract][Full Text] [Related]
24. "Solving the puzzle" of current HAART: what key strategic trials are needed?
Carosi G; Torti C
New Microbiol; 2004 Apr; 27(2 Suppl 1):127-30. PubMed ID: 15646075
[TBL] [Abstract][Full Text] [Related]
25. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients.
Fisher SD; Kanda BS; Miller TL; Lipshultz SE
Am J Cardiovasc Drugs; 2011 Dec; 11(6):383-94. PubMed ID: 22149317
[TBL] [Abstract][Full Text] [Related]
28. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
Pozniak A; Gazzard B; Anderson J; Babiker A; Churchill D; Collins S; Fisher M; Johnson M; Khoo S; Leen C; Loveday C; Moyle G; Nelson M; Peter B; Phillips A; Pillay D; Wilkins E; Williams I; Youle M;
HIV Med; 2003 Oct; 4 Suppl 1():1-41. PubMed ID: 14511246
[No Abstract] [Full Text] [Related]
29. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Grover SA; Coupal L; Gilmore N; Mukherjee J
Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
[TBL] [Abstract][Full Text] [Related]
30. [Lipid profile of atazanavir].
Martínez Chamorro E
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():34-40. PubMed ID: 20116615
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologic consideration for the use of antiretroviral agents in the elderly.
Rhee MS; Greenblatt DJ
J Clin Pharmacol; 2008 Oct; 48(10):1212-25. PubMed ID: 18812611
[TBL] [Abstract][Full Text] [Related]
32. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
33. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.
Calza L; Colangeli V; Manfredi R; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2016 Jun; 71(6):1451-65. PubMed ID: 26846208
[TBL] [Abstract][Full Text] [Related]
34. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
Smith KY
J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
[TBL] [Abstract][Full Text] [Related]
35. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
Rotger M; Bayard C; Taffé P; Martinez R; Cavassini M; Bernasconi E; Battegay M; Hirschel B; Furrer H; Witteck A; Weber R; Ledergerber B; Telenti A; Tarr PE;
Circ Cardiovasc Genet; 2009 Dec; 2(6):621-8. PubMed ID: 20031643
[TBL] [Abstract][Full Text] [Related]
36. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Samineni D; Fichtenbaum CJ
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
[TBL] [Abstract][Full Text] [Related]
37. Strategies for management and treatment of dyslipidemia in HIV/AIDS.
Sax PE
AIDS Care; 2006 Feb; 18(2):149-57. PubMed ID: 16338773
[TBL] [Abstract][Full Text] [Related]
38. The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is 'the more the merrier'?
Martin F; Taylor GP
J Antimicrob Chemother; 2009 Nov; 64(5):895-900. PubMed ID: 19706669
[TBL] [Abstract][Full Text] [Related]
39. Evaluating and managing cardiovascular disease risk factors in HIV-infected patients.
Top HIV Med; 2010 Dec; 18(5):164-8. PubMed ID: 21245517
[TBL] [Abstract][Full Text] [Related]
40. [Anaesthesia for HIV-infected patients].
Bornard L; Blay M; Roger PM; Raucoules-Aimé M; Carles M
Ann Fr Anesth Reanim; 2011 Jun; 30(6):501-11. PubMed ID: 21684100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
